Results 151 to 160 of about 4,735 (197)
Some of the next articles are maybe not open access.
Drugs & Aging, 2003
Dutasteride, a potent inhibitor of type 1 and 2 5alpha-reductase, reduced dihydrotestosterone levels by >90% in 85% of patients following 1 years' administration of oral dutasteride 0.5 mg/day. A combined analysis of three placebo-controlled clinical studies conducted in patients with benign prostatic hyperplasia (BPH) found sustained improvements in ...
Hannah C, Evans, Karen L, Goa
+7 more sources
Dutasteride, a potent inhibitor of type 1 and 2 5alpha-reductase, reduced dihydrotestosterone levels by >90% in 85% of patients following 1 years' administration of oral dutasteride 0.5 mg/day. A combined analysis of three placebo-controlled clinical studies conducted in patients with benign prostatic hyperplasia (BPH) found sustained improvements in ...
Hannah C, Evans, Karen L, Goa
+7 more sources
The Cardiovascular Safety of Dutasteride
Journal of Urology, 2017Randomized controlled trials suggest an increased risk of heart failure with dutasteride, which inhibits both the type 1 and type 2 isoforms of 5α-reductase. In contrast, no such association has been suggested for finasteride, which selectively inhibits the type 2 isoform.
J Michael Paterson, Anjie Huang
exaly +3 more sources
Dutasteride in Androgenetic Alopecia: An Update
Current Clinical Pharmacology, 2017Androgenetic alopecia is a common condition characterized by thinning of scalp hair. Conversion of testosterone to dihydrotestosterone, a more potent androgen, by the enzyme 5-α-reductase is responsible for underlying pathogenesis. Dutasteride, a synthetic 4-azasteroid, is a selective and competitive inhibitor of both type-1 and type-2 isoenzymes of 5 ...
Tasleem Arif +2 more
exaly +3 more sources
Impurity profile study of dutasteride
Die Pharmazie, 2007During the process development of dutasteride in the laboratory analysis showed some impurity peaks in HPLC ranging from 0.05 to 0.1%. The same samples were analyzed by LCMS method and identified peak at m/z 508 (desmethyl dutasteride), 530 (dihydro dutasteride) and 528 (isomer of dutasteride).
K, Satyanarayana +3 more
openaire +2 more sources
Drugs, 2008
Dutasteride (Avodart), an oral synthetic 4-azasteroid, is a potent, selective, irreversible inhibitor of type 1 and type 2 5alpha-reductase (5AR), the enzyme that converts testosterone to dihydrotestosterone (DHT) intracellularly. Although type 2 5AR predominates, both isoenzymes are overexpressed in prostate tissue in benign prostatic hyperplasia (BPH)
Susan J, Keam, Lesley J, Scott
openaire +2 more sources
Dutasteride (Avodart), an oral synthetic 4-azasteroid, is a potent, selective, irreversible inhibitor of type 1 and type 2 5alpha-reductase (5AR), the enzyme that converts testosterone to dihydrotestosterone (DHT) intracellularly. Although type 2 5AR predominates, both isoenzymes are overexpressed in prostate tissue in benign prostatic hyperplasia (BPH)
Susan J, Keam, Lesley J, Scott
openaire +2 more sources
Drugs & Aging, 2012
The 5α-reductase inhibitor dutasteride and the α(1)-adrenergic receptor antagonist tamsulosin are available as a fixed-dose combination for use in men with symptomatic benign prostatic hyperplasia (BPH) and an enlarged prostate. Dutasteride 0.5 mg/day plus tamsulosin 0.4 mg/day improved lower urinary tract symptoms (LUTS) to a significantly greater ...
openaire +2 more sources
The 5α-reductase inhibitor dutasteride and the α(1)-adrenergic receptor antagonist tamsulosin are available as a fixed-dose combination for use in men with symptomatic benign prostatic hyperplasia (BPH) and an enlarged prostate. Dutasteride 0.5 mg/day plus tamsulosin 0.4 mg/day improved lower urinary tract symptoms (LUTS) to a significantly greater ...
openaire +2 more sources
Dutasteride and Prostate Cancer Risk
Current Urology Reports, 2010In a previously published and heavily discussed paper [1], the type 2 5-α-reductase inhibitor (5ARI) finasteride was shown to reduce the risk of prostate cancer by a substantial 25% as compared to placebo in men at no known risk of developing prostate cancer.
openaire +2 more sources